IOVA

6.9005.61%
MW

Michael Weiser

Independent Director

Dr. Michael Weiser, M.D., Ph.D., is the Co-Founder and Director at Foresight Biotherapeutics, Inc. He is a Principal Executive Officer of Riverside Therapeutics Inc. and has been its President since September 2004. Dr. Weiser was employed at Paramount Capital Investments L.L.C. He serves as an Executive Vice President and a Director of Paramount Acquisition Corp. He served as President and Secretary at Kodiak Sciences, Inc. since August 14, 2005 and as its Principal Executive Officer. He served as Director of Research at Paramount Capital Asset Management, Inc. and Paramount BioCapital Asset Management, Inc. He served as Vice President at Manhattan Pharmaceuticals Inc. Dr. Weiser served as the Chief Medical Officer at Manhattan Research Development and Innovative Drug Delivery Systems, Inc. from its inception until August 2001. He has been the Chairman of Chelsea Therapeutics International Ltd. since July 2012. He served as the Chairman of Chelsea Therapeutics Inc., until February 2007 and has been its Director since February 2004. He has been a Director of Manhattan Pharmaceuticals Inc. Dr. Weiser has been a Director at Innovative Drug Delivery Systems, Inc. since June 2000; Riverside Therapeutics Inc. since September 2004. He served as Director of ZIOPHARM Oncology, Inc. from September 2005 to March 12, 2018. He has been an Independent Director of Iovance Biotherapeutics, Inc. since March 15, 2018. He has been an Independent Director of Emisphere Technologies, Inc. since October 12, 2005. He serves as a Director of Hana Biosciences Inc., (formerly Email Real Estate.com Inc.). He served as a Director of Javelin Pharmaceuticals Inc. since June 2000. He served as Director of VioQuest Pharmaceuticals Inc. since February 2003 until February 09, 2009. He has served as a member of Chiral Quest's management committee since July 2002. Dr. Weiser is also a Member of Orion Biomedical GP, LLC and serves on the board of directors of several privately held companies. He served as a Director of Manhattan Research Development since December 2001. He served as Director of Talon Therapeutics, Inc. from December 2002 to June 07, 2010. He served as Director of CytRx Oncology Corporation. Dr. Weiser completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience at New York University School of Medicine and from July 1997 to July 1998, he completed his post-graduate medical training at the Department of Obstetrics and Gynecology and Primary Care, at New York University Medical Center. Dr. Weiser received an M.D. from New York University School of Medicine(NYU Elaine A. and Kenneth G. Langone Medical Center) and a Ph.D. in Molecular Neurobiology from Cornell University Medical College He holds a Bachelor of Arts in psychology from University of Vermont. He is the founder and has been a principal of Actin Biomed LLC since 2006. Actin Biomed is a healthcare investment firm focused on the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital, Inc., a pharmaceutical development and healthcare investment firm.

Positions